Bio‑Techne and Oxford Nanopore extended and broadened their partnership through 2032 to develop a portfolio of targeted nanopore sequencing kits for screening and diagnosing heritable genetic disorders. The agreement expands beyond carrier screening into a broader diagnostic product slate and grants Bio‑Techne broader commercial rights to build clinical offerings on nanopore long‑read capabilities. Separately, MyHeritage announced a move to whole‑genome sequencing (WGS) for consumer tests, partnering with Gene by Gene and Ultima Genomics to process more than a million WGS tests per year using Ultima’s UG100 platform. The consumer push to WGS and the Bio‑Techne clinical roadmap together signal growing market demand for long‑read and high‑throughput whole‑genome solutions across clinical and consumer segments. Both deals reflect industry efforts to industrialize sequencing chemistry, sample prep, and informatics across high‑volume clinical and consumer endpoints, while highlighting commercial strategies to pair platforms with application‑specific assay kits.